Non-exclusive rebate agreement for Aflibercept
Original notice title
Germany – Pharmaceutical products – Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Fertigspritze
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No minimum volume guarantee; actual demand may be low or unpredictable.
Procedure is not a public procurement under EU directives; standard procurement remedies may not apply.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Provision of Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as injection solution in pre-filled syringes.
- Non-exclusive rebate agreement under §130a Abs. 8 SGB V.
Show full summary
Open-House model for non-exclusive rebate agreements for the pharmaceutical product Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as injection solution in a pre-filled syringe, issued by AOK PLUS for the regions of Saxony and Thuringia. The procedure is not a public procurement under EU directives but published for transparency. Participation is open to all interested pharmaceutical companies meeting conditions. No minimum quantities guaranteed. The agreement ends at 31.12.2026. Initial submission window: 25 Nov to 3 Dec 2025, with continuous submissions thereafter.
Risks
No minimum volume guarantee; actual demand may be low or unpredictable.
Procedure is not a public procurement under EU directives; standard procurement remedies may not apply.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG.
Eligibility
- Submit self-declarations on exclusion grounds (§§123, 124 GWB) and Russian sanctions.
Administrative
- Maintain strict confidentiality of procurement documents.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive rebate agreement for Aflibercept
Provision of Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as injection solution in a pre-filled syringe under non-exclusive rebate agreements.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Fertigspritze
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 11 Nov 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 749886-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No minimum volume guarantee; actual demand may be low or unpredictable.
Procedure is not a public procurement under EU directives; standard procurement remedies may not apply.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications